British researchers said on November 10 they had identified proteins in the coronavirus that are recognized by T-cells of people who are exposed to the virus but resist infection, possibly providing a new target for vaccine developers.
British scientists identified a version of a gene that may be associated with double the risk of lung failure from Covid-19, a finding that provides new insights into why some people are more susceptible than others to severe illness and which opens possibilities for targeted medicine.
Novartis forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
Novavax Inc. said on Oct. 27 the company had completed the real-time submission of an application for the authorization of the Covid-19 vaccine candidate NVX-CoV2373 in the United Kingdom.
The UK Health Security Agency designated a Delta coronavirus subvariant called AY.4.2 as a “Variant Under Investigation,” saying there was some evidence that it could be more transmissible than Delta.
Pfizer, Moderna, and AstraZeneca have been running “dress rehearsals” by adapting their current formulations of Covid-19 vaccines to match present known SARS-CoV-2 variants.
British health authorities, as well as global experts, are closely watching a subtype of the Delta variant that appears to be rising in the UK.
The Delta variant of the coronavirus does not appear to cause more severe disease in children than earlier forms of the virus, a UK study suggests. Another study found that in Covid-19 survivors, important components of the body’s immune response called memory B cells continue to evolve and get stronger for at least several months, producing highly potent antibodies that can neutralize new variants of the virus.
On World Mental Health Day (October 10), medical health charity You Okay, Doc? and health communications agency VMLY&Rx pledge their support to physicians worldwide, calling for more awareness and support for the mental health of doctors.
Britain’s state-run National Health Service will on Sept. 13 begin the world’s biggest trial of Grail Inc.’s flagship Galleri blood test that can be used to detect more than 50 types of cancer before symptoms appear.
